Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.
Nuclear imaging is used in the diagnosis and treatment of various diseases such as heart disease, cancer, and brain disorders by taking a small amount of radioactive particle and then determining the response with external detectors such as gamma cameras. These devices help in determining the severity and progression of the disease so that effective medication program can be developed.

The global Nuclear Imaging market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Nuclear Imaging volume and value at global level, regional level and company level. From a global perspective, this report represents overall Nuclear Imaging market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Nuclear Imaging in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Nuclear Imaging manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GE
Siemens Healthcare
Philips Healthcare
Toshiba Medical Systems Corporation
Hitachi Medical
Digirad
DDD-Diagnostics
Neusoft Medical Systems
Mediso
SurgicEye
CMR Naviscan

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Positron Emission Tomography
Single-photon Emission Computed Tomography
Planar Scintigraphy Systems

Segment by Application
Oncology
Cardiology
Neurology
Others